Actively Recruiting
Phase 2 Study of Chidamide and Linperlisib for Treating Refractory or Relapsed Follicular Lymphoma in Adults
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-19
33
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the safety and effectiveness of combining Chidamide with Linperlisib to treat patients with refractory and relapsed follicular lymphoma. This Phase 2, open-label trial aims to assess how well this drug combination works by measuring outcomes like complete response, overall survival, and progression-free survival. Participants will receive Chidamide orally twice a week at 20mg and Linperlisib once daily at 80mg following a schedule of two weeks on treatment and two weeks off, repeating every 28 days. This study is conducted at multiple centers under the sponsorship of The First Affiliated Hospital of Xiamen University. During the study, participants will undergo evaluations including imaging scans like CT or MRI to measure tumor lesions, as well as assessments of response rates and survival over up to 24 months. Researchers will monitor for any side effects and treatment safety throughout the trial period. Participants must be able to follow the study protocol and provide informed consent to join.
CONDITIONS
Brief Title
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Research Team
B
Bing Xu
Z
Zhifeng Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
